Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Biohaven Announces Positive Results From Ongoing Rimegepant Long-term Safety Study
LPNEWS

Biohaven Announces Positive Results From Ongoing Rimegepant Long-term Safety Study

by prnewswire.com posted 11months ago 65 views
NEW HAVEN, Conn., Dec. 10, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced initial positive results from its ongoing long-term, open-label safety study of its oral calcitonin gene-related peptide (CGRP) receptor antagonist, rimegepant, for...

In this article